Exact Mass: 389.1686

Exact Mass Matches: 389.1686

Found 139 metabolites which its exact mass value is equals to given mass value 389.1686, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Balofloxacin

Balofloxacin, (R)-

C20H24FN3O4 (389.1751)


D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

   

Diphemanil Methylsulfate

Diphenmanil (methylsulfate)

C21H27NO4S (389.1661)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics Diphemanil methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat. IC50 value: Target: mAChR Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. M3 receptors are located in the smooth muscles of the blood vessels, as well as in the lungs. This means they cause vasodilation and bronchoconstriction. They are also in the smooth muscles of the gastrointestinal tract (GIT), which help in increasing intestinal motility and dilating sphincters. The M3 receptors are also located in many glands which help to stimulate secretion in salivary glands and other glands of the body.

   

2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

4-(furan-2-yl)-10-[3-(4-methoxyphenyl)propyl]-3,5,6,8,10,11-hexaazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-7-amine

C20H19N7O2 (389.16)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].

   

Balofloxacin

1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

C20H24FN3O4 (389.1751)


D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

   

Cytidine, 2'-deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)-

N-{1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}-2-propylpentanamide

C17H25F2N3O5 (389.1762)


   

Ilginatinib

N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine

C21H20FN7 (389.1764)


   

Reproterol

7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C18H23N5O5 (389.1699)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents

   

Xanthoanthrafil

Xanthoanthrafil

C19H23N3O6 (389.1587)


   
   
   

Asperdiazapinone B

Asperdiazapinone B

C23H23N3O3 (389.1739)


   

Asperdiazapinone D

Asperdiazapinone D

C23H23N3O3 (389.1739)


   

3-(benzoyloxy-phenyl-methyl)-1-methyl-4-(1-methyl-1H-imidazol-4-yl)-pyrrolidin-2-one|Cynodin|cynodine

3-(benzoyloxy-phenyl-methyl)-1-methyl-4-(1-methyl-1H-imidazol-4-yl)-pyrrolidin-2-one|Cynodin|cynodine

C23H23N3O3 (389.1739)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

O4-Pyridyloxobutyl-thymidine

O4-Pyridyloxobutyl-thymidine

C19H23N3O6 (389.1587)


   

3-Pyridyloxobutyl-thymidine

3-Pyridyloxobutyl-thymidine

C19H23N3O6 (389.1587)


   

Ala Gly Gly Trp

(2S)-2-(2-{2-[(2S)-2-aminopropanamido]acetamido}acetamido)-3-(1H-indol-3-yl)propanoic acid

C18H23N5O5 (389.1699)


   

Ala Gly Trp Gly

2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]acetic acid

C18H23N5O5 (389.1699)


   

Ala Trp Gly Gly

2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]acetamido}acetic acid

C18H23N5O5 (389.1699)


   

Gly Ala Gly Trp

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)propanamido]acetamido}-3-(1H-indol-3-yl)propanoic acid

C18H23N5O5 (389.1699)


   

Gly Ala Trp Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-(1H-indol-3-yl)propanamido]acetic acid

C18H23N5O5 (389.1699)


   

Gly Gly Ala Trp

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]propanamido]-3-(1H-indol-3-yl)propanoic acid

C18H23N5O5 (389.1699)


   

Gly Gly Trp Ala

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-indol-3-yl)propanamido]propanoic acid

C18H23N5O5 (389.1699)


   

Gly Trp Ala Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-indol-3-yl)propanamido]propanamido]acetic acid

C18H23N5O5 (389.1699)


   

Gly Trp Gly Ala

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-indol-3-yl)propanamido]acetamido}propanoic acid

C18H23N5O5 (389.1699)


   
   
   
   
   
   
   
   
   
   

Trp Ala Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]propanamido]acetamido}acetic acid

C18H23N5O5 (389.1699)


   

Trp Gly Ala Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]acetamido}propanamido]acetic acid

C18H23N5O5 (389.1699)


   

Trp Gly Gly Ala

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]acetamido}acetamido)propanoic acid

C18H23N5O5 (389.1699)


   

ZM 336372

3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-benzamide

C23H23N3O3 (389.1739)


ZM 336372 is a potent inhibitor of the protein kinase c-Raf. The IC50 value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.

   

boc-3-(1-pyrenyl)-l-alanine

boc-3-(1-pyrenyl)-l-alanine

C24H23NO4 (389.1627)


   

LY2334737

Cytidine, 2-deoxy-2,2-difluoro-N-(1-oxo-2-propylpentyl)-

C17H25F2N3O5 (389.1762)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor

   

Diphenyl(1-propoxy)essigsaeure-piperid-4-yl-esterhydrochlorid

Diphenyl(1-propoxy)essigsaeure-piperid-4-yl-esterhydrochlorid

C22H28ClNO3 (389.1758)


   
   
   

3-(3,4-DIETHOXY-PHENYL)-6-(4-METHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE

3-(3,4-DIETHOXY-PHENYL)-6-(4-METHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE

C23H23N3O3 (389.1739)


   

3-Quinolinecarboxylic acid, 1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-(3-Methyl-1-piperazinyl)-4-oxo-

3-Quinolinecarboxylic acid, 1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-(3-Methyl-1-piperazinyl)-4-oxo-

C20H24FN3O4 (389.1751)


   

PHENYL (4-(4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL)PHENYL)CARBAMATE

PHENYL (4-(4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL)PHENYL)CARBAMATE

C23H23N3O3 (389.1739)


   

ISO-PROPYL 2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE

ISO-PROPYL 2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE

C17H27NO9 (389.1686)


   
   

boc-3-(1-pyrenyl)-d-alanine

boc-3-(1-pyrenyl)-d-alanine

C24H23NO4 (389.1627)


   

Nicardipine Methyl Amino Derivative

Nicardipine Methyl Amino Derivative

C19H23N3O6 (389.1587)


   

N-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-N,N,N-trimethyl-1,3-propanediamine

N-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-N,N,N-trimethyl-1,3-propanediamine

C21H28ClN3S (389.1692)


   

Azilsartan Impurity

Azilsartan Impurity

C23H23N3O3 (389.1739)


   

Ethyl 3-amino-2-{[(2-carbamoyl-4-biphenylyl)methyl]amino}benzoat e

Ethyl 3-amino-2-{[(2-carbamoyl-4-biphenylyl)methyl]amino}benzoat e

C23H23N3O3 (389.1739)


   

Brepocitinib

Brepocitinib

C18H21F2N7O (389.1776)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C308 - Immunotherapeutic Agent

   

Ilginatinib

Ilginatinib

C21H20FN7 (389.1764)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor

   

Balofloxacin, (R)-

Balofloxacin, (R)-

C20H24FN3O4 (389.1751)


   

Reproterol

Reproterol

C18H23N5O5 (389.1699)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents

   

L-alanyl-gamma-D-glutamyl-meso-diaminopimelate

L-alanyl-gamma-D-glutamyl-meso-diaminopimelate

C15H25N4O8- (389.1672)


   

(2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate

(2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate

C21H25O7- (389.16)


   

L-alanyl-gamma-D-glutamyl-meso-diaminopimelate(1-)

L-alanyl-gamma-D-glutamyl-meso-diaminopimelate(1-)

C15H25N4O8- (389.1672)


   

4-[3-(2,5-Dimethyl-1-pyrrolyl)-4-(1-pyrrolidinyl)phenyl]sulfonylmorpholine

4-[3-(2,5-Dimethyl-1-pyrrolyl)-4-(1-pyrrolidinyl)phenyl]sulfonylmorpholine

C20H27N3O3S (389.1773)


   

(3aS)-2-m-anisyl-10,10-dimethyl-4,9-dihydro-3aH-imidazo[1,5-b]-carboline-1,3-quinone

(3aS)-2-m-anisyl-10,10-dimethyl-4,9-dihydro-3aH-imidazo[1,5-b]-carboline-1,3-quinone

C23H23N3O3 (389.1739)


   

3-[1-[Oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one

3-[1-[Oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one

C23H23N3O3 (389.1739)


   

3-(4-fluorophenyl)-N-[3-(1-imidazolyl)propyl]-1-phenyl-4-pyrazolecarboxamide

3-(4-fluorophenyl)-N-[3-(1-imidazolyl)propyl]-1-phenyl-4-pyrazolecarboxamide

C22H20FN5O (389.1652)


   

3-[2-(2,4-Dimethyl-3-furanyl)-2-oxoethyl]-3-hydroxy-1-(2-phenylethyl)-2-indolone

3-[2-(2,4-Dimethyl-3-furanyl)-2-oxoethyl]-3-hydroxy-1-(2-phenylethyl)-2-indolone

C24H23NO4 (389.1627)


   

(11aS)-2-(4-methoxybenzyl)-5,5-dimethyl-5,6,11,11a-tetrahydro-1H-imidazo[1,5:1,6]pyrido[3,4-b]indole-1,3(2H)-dione

(11aS)-2-(4-methoxybenzyl)-5,5-dimethyl-5,6,11,11a-tetrahydro-1H-imidazo[1,5:1,6]pyrido[3,4-b]indole-1,3(2H)-dione

C23H23N3O3 (389.1739)


   

(15R)-13-[(3-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

(15R)-13-[(3-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

C23H23N3O3 (389.1739)


   

(15R)-13-[(4-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

(15R)-13-[(4-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

C23H23N3O3 (389.1739)


   

(15S)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

(15S)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

C23H23N3O3 (389.1739)


   

(15R)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

(15R)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione

C23H23N3O3 (389.1739)


   
   
   
   
   

(5Z)-5-{(2E)-3-[4-(dimethylamino)phenyl]prop-2-en-1-ylidene}-1-(3,5-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione

(5Z)-5-{(2E)-3-[4-(dimethylamino)phenyl]prop-2-en-1-ylidene}-1-(3,5-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione

C23H23N3O3 (389.1739)


   

(6S,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6R,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6R,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

4-[4-[(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

(1R,5S)-N-(3-fluorophenyl)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1R,5S)-N-(3-fluorophenyl)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C22H20FN5O (389.1652)


   

(6R,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6S,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6S,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6R,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

(6S,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H23N3O3 (389.1739)


   

4-[4-[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   

4-[4-[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

4-[4-[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile

C23H23N3O3 (389.1739)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

SCH 442416

2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

C20H19N7O2 (389.16)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].

   

AKT-IN-6

AKT-IN-6

C22H20FN5O (389.1652)


AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).

   

[1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate

[1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate

C23H23N3O3 (389.1739)


   

(2s,3r,4r,5r,6s)-2-({6-[(z)-(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol

(2s,3r,4r,5r,6s)-2-({6-[(z)-(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol

C19H23N3O6 (389.1587)


   

(2s,10r,12s)-6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one

(2s,10r,12s)-6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one

C23H23N3O3 (389.1739)


   

n-(2-{2-[(4-hydroxy-1-methyl-2-oxoquinolin-3-yl)methyl]-1h-indol-3-yl}ethyl)ethanimidic acid

n-(2-{2-[(4-hydroxy-1-methyl-2-oxoquinolin-3-yl)methyl]-1h-indol-3-yl}ethyl)ethanimidic acid

C23H23N3O3 (389.1739)


   

6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one

6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one

C23H23N3O3 (389.1739)


   

2-({6-[(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol

2-({6-[(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol

C19H23N3O6 (389.1587)


   

(3s)-3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol

(3s)-3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol

C23H23N3O3 (389.1739)


   

3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol

3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol

C23H23N3O3 (389.1739)


   

(s)-[(3s,4r)-1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate

(s)-[(3s,4r)-1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate

C23H23N3O3 (389.1739)